Philogen SpA (MIL:PHIL) Short-Term Debt: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:PHIL Philogen SpA MIL:PHIL
61 GF Score
Price €25.70
GF Value €229.26
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Philogen SpA Short-Term Debt?

Philogen SpA MIL:PHIL +0.59% 61 Short-Term Debt is €0.0 Mil as of Dec. 2025. GuruFocus rates MIL:PHIL with a GF Score™ of 61/100 and a GF Value™ of €229.26 (Possible Value Trap). The stock has 4 warning signs investors should review.

Philogen SpA's Short-Term Debt for the quarter that ended in Dec. 2025 was €0.0 Mil.

Philogen SpA's quarterly Short-Term Debt stayed the same from Dec. 2024 (€0.0 Mil) to Jun. 2025 (€0.0 Mil) but then increased from Jun. 2025 (€0.0 Mil) to Dec. 2025 (€0.0 Mil).

Philogen SpA's annual Short-Term Debt stayed the same from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) but then increased from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€0.0 Mil).

Philogen SpA Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Philogen SpA Short-Term Debt Related Terms

Philogen SpA Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Philogen SpA's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Philogen SpA Short-Term Debt Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.04

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.95 0.00 0.00 0.04
MIL:PHIL
61GF Score
Philogen SpA MIL:PHIL
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €0.0 Mil mean?
Philogen SpA (MIL:PHIL) has a Short-Term Debt of €0.0 Mil as of Dec. 2025.
Is Philogen SpA's Short-Term Debt too high?
Philogen SpA's current Short-Term Debt is €0.0 Mil. Overall, Philogen SpA has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's Short-Term Debt compare to VRTX and REGN?
Philogen SpA's Short-Term Debt of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Philogen SpA's current Short-Term Debt is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €229.26, compared to a current price of €25.70 — trading 88.8% below its estimated fair value. The current Short-Term Debt is €0.0 Mil. Philogen SpA's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current Short-Term Debt is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Philogen SpA (MIL:PHIL) Overvalued in 2026?

Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued. The current stock price of €25.70 is trading 88.8% below its estimated GF Value™ of €229.26. GuruFocus considers Philogen SpA to be Possible Value Trap.

Key valuation signals for MIL:PHIL:

  • Short-Term Debt: €0.0 Mil
  • GF Value™: €229.26 vs. price of €25.70 (88.8% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Philogen SpA Business Description

Other Exchanges 78Q:Germany
Address Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
61GF Score

Get the complete analysis for MIL:PHIL

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.70
Price
€229.26
GF Value